April 7, 2005 — -- The Food and Drug Administration asked Pfizer Inc. to pull the painkiller Bextra off the shelves today in a voluntary recall after considering data that the drug poses ...

A second cancer study using the drug found no increased heart risk with patients taking 400 mg of Celebrex per day. The standard recommended dose for Celebrex to treat osteoarthritis arthritis — the ...

NEW ORLEANS — A new study gives some reassurance to arthritis sufferers who want pain relief but are worried about side effects. It finds that Celebrex, a drug similar to ones withdrawn 12 years ago ...

NEW YORK (Reuters) - Pfizer Inc has reached tentative deals with some patients who claim to have suffered heart attacks and strokes from taking the company's Celebrex and Bextra pain medicines, the ...

Aug. 4, 2005 — The U.S. Food and Drug Administration (FDA) has approved valsartan to reduce cardiovascular mortality in patients with left ventricular dysfunction/failure following a myocardial ...

The safety of Celebrex and other pain relievers was questioned Wednesday as scientists in the United States and regulatory agencies in Europe said they feared such drugs might raise the same risk of ...

New York, NY - Celecoxib (Celebrex, Pfizer) is one of the victors of the coxib scare. It gained prescriptions when rofecoxib (Vioxx, Merck) was pulled from the market and again when Pfizer's own ...

Strides Pharma Global, Singapore, has received approval for celecoxib capsules, 100 mg, 200 mg and 400 mg from the Food and Drug Administration. The product is the generic of Upjohn’s Celebrex. The ...

NEW YORK Pfizer's surprise announcement of possible health risks connected with its Celebrex drug pushed stocks lower in heavy trading Friday, renewing investors' concerns over the pharmaceutical ...

NEW YORK — Pfizer's surprise announcement of possible health risks connected with its Celebrex drug pushed stocks lower in heavy trading Friday, renewing investors' concerns over the pharmaceutical ...

NEW YORK — Pfizer's surprise announcement of possible health risks connected with its Celebrex drug pushed stocks lower in heavy trading Friday, renewing investors' concerns over the pharmaceutical ...